OraSure Technologies Files For FDA Approval of OraQuick Rapid Hepatitis C Test

When Approved, OraQuick(R) HCV is Expected to be the First Rapid HCV Test in U.S.

BETHLEHEM, Pa.--(BUSINESS WIRE)--Oct. 28, 2008--OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that it has submitted a pre-market approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for a rapid test for antibodies to the Hepatitis C virus ("HCV") utilizing OraSure Technologies' OraQuick(R) technology platform. When approved, the OraQuick(R) HCV test is expected to be the first rapid HCV test approved by the FDA for use in the United States.

The Company is seeking FDA approval for use of its OraQuick(R) HCV test on five specimen types - oral fluid, fingerstick whole blood, venous whole blood, plasma and serum. The submission reflects the successful completion of clinical studies which include data from over 3,000 subjects.

The Company also intends to submit a request for CE mark approval of the OraQuick(R) HCV test within the next several months. CE mark approval is needed to sell the test in the European Union.

"The completion of our FDA submission for the OraQuick(R) HCV test is the result of a tremendous effort by our regulatory, research and development and operations groups, and we are very grateful for all of their efforts," said Douglas A. Michels, President and CEO of OraSure Technologies. "We believe the market opportunity for a rapid HCV test, both here in the U.S. and around the world, is very significant and this submission represents the achievement of an important milestone towards commercialization. We look forward to launching this product in the U.S. in collaboration with Schering-Plough Corporation once FDA approval is obtained."

On a world-wide basis, there are an estimated 180 million people who are chronically infected with HCV, with an estimated three to four million individuals newly infected each year. The prevalence of Hepatitis C infection is estimated to be four times that of HIV around the world.

According to the World Health Organization, as many as fifty percent of persons infected with HCV are undiagnosed and up to eighty percent who have HCV show no signs or symptoms. In the U.S., there are an estimated four million Americans, or 1.3 percent of the population, that are or have been infected with HCV. According to the Centers for Disease Control and Prevention ("CDC"), new infections in the U.S. are estimated at approximately 20,000 per year.

As previously announced, OraSure has entered into agreements with Schering-Plough Corporation to collaborate on the development and promotion of the OraQuick(R) HCV test. Under the terms of these agreements, the Company has been and will be reimbursed by Schering-Plough for a portion of its costs to develop the test and obtain regulatory approvals, and Schering-Plough will provide detailing and other promotional support for the test in the physicians' office markets in the United States and internationally.

About Hepatitis C

Hepatitis C is the major cause of acute Hepatitis and chronic liver disease and, if left undiagnosed and treated, can lead to cirrhosis of the liver, liver cancer, liver failure and death. According to the CDC it is estimated that seventy-five to eighty-five percent of those people who become infected with the hepatitis C virus develop chronic infection, and five to twenty percent eventually develop cirrhosis of the liver.

Although HCV is a significant health issue, it is a curable disease. With current treatment therapies, the rates of sustained viral clearance are as high as fifty percent in cases of infection by Genotype 1, the most common form of HCV, and as high as eighty percent with the less commonly occurring Genotypes 2 and 3 of the virus. New therapies are under development which may improve these treatment rates. OraSure believes the key to improving public health with respect to this disease is early diagnosis through wide-spread testing.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the public health and life insurance markets for the detection of antibodies to HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

Important Information

This press release contains certain forward-looking statements, including with respect to products, testing and regulatory submissions and approvals. Actual results could be significantly different. Factors that could affect results include the ability to market and sell products; changes in relationships, including disputes or disagreements, with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements for the Company's products; impact of replacing distributors; inventory levels at distributors and other customers; impact of replacing distributors; inventory levels at distributors and other customers; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance; continued bulk purchases by customers, including governmental agencies, and the ability to fully deploy those purchases in a timely manner; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties or products required for use of our products; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; history of losses and ability to achieve sustained profitability; volatility of the Company's stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including changes in international funding sources; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to retain qualified personnel; exposure to patent infringement, product liability, and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to identify, complete and realize the full benefits of potential acquisitions; and general political, business and economic conditions. These and other factors are discussed more fully in the Securities and Exchange Commission ("SEC") filings of OraSure Technologies, including its registration statements, its Annual Report on Form 10-K for the year ended December 31, 2007, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

CONTACT: OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
investorinfo@orasure.com
or
Media Contact:
Zer0 to 5ive for OraSure Technologies
Jennifer Moritz
917-748-4006
jmoritz@0to5.com

SOURCE: OraSure Technologies, Inc.